首页> 外文期刊>Reumatologia >A?fine line between macrophage activation syndrome and multisystem inflammatory syndrome in children – literature review based on two case reports
【24h】

A?fine line between macrophage activation syndrome and multisystem inflammatory syndrome in children – literature review based on two case reports

机译:一种巨噬细胞激活综合征与儿童多系统炎症综合征之间的细纹 - 基于两个案例报告的文献综述

获取原文
       

摘要

Multisystem inflammatory syndrome in children is a?newly described condition temporarily associated with severe acute respiratory syndrome coronavirus 2. The primary observations indicated coronavirus disease 2019 infection in children to be mild. However, recent reports have revealed a?correlation between multisystem inflammatory symptoms and coronavirus infection. The manifestation of the disease is similar to Kawasaki disease, toxic shock syndrome and macrophage activation syndrome. Treatment includes intravenous corticosteroids, immunoglobulin and biological therapy (anakinra, tocilizumab, infliximab). In this article we compare world reports of multisystem inflammatory syndrome in children to case reports of two patients who were hospitalized recently at the Department of Paediatric Cardiology and Rheumatology. In the course of diagnostics they presented numerous symptoms which required differentiation from multisystem inflammatory syndrome in children.
机译:儿童的多系统炎症综合征是一种新描述的病症,暂时与严重急性呼吸综合征冠状病毒2.初级观察表明冠状病毒2019年儿童感染患者轻度。 然而,最近的报告显示了多系统炎症症状与冠状病毒感染之间的相关性。 该疾病的表现与川崎疾病,毒性休克综合征和巨噬细胞激活综合征类似。 治疗包括静脉内皮质类固醇,免疫球蛋白和生物治疗(Anakinra,Tocilizumab,Infliximab)。 在本文中,我们比较了儿童多系统炎症综合征的世界报告,以便报告最近在儿科心脏病和风湿病学部门住院的两名患者。 在诊断过程中,他们介绍了许多症状,这些症状需要与儿童多系统炎症综合征不同。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号